A Drug Device Combination Products Market Forecasts to 2030 – Global Analysis By Product (Infusion Pumps, Orthopedic Combination Products, Transdermal Patches, Photodynamic Therapy Devices, Drug Eluting Stents, Wound Care Products

Drug Device Combination Products Market Forecasts to 2030 – Global Analysis By Product (Infusion Pumps, Orthopedic Combination Products, Transdermal Patches, Photodynamic Therapy Devices, Drug Eluting Stents, Wound Care Products, Antimicrobial Catheters and Other Products), Application, End User and By Geography


According to Stratistics MRC, the Global Drug Device Combination Products Market is accounted for $141.7 billion in 2023 and is expected to reach $292.4 billion by 2030 growing at a CAGR of 10.9% during the forecast period. Drug-device combination products are medical devices that combine a device and active medicinal substances to form a ""single entity"" by chemical or physical means. Due to precise medication delivery, local administration, and customized treatment, these solutions contribute to the safer, more efficient management and treatment of a number of illnesses. Drug-eluting stents, infusion pumps, inhalers, transdermal delivery systems, prefilled syringes, and other popular drug-device combo products are instances.

According to the IDF 2021, approximately 537 million adults are living with diabetes, and the number of people adults living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.

Market Dynamics

Driver

A rise in product launches

The market for drug-device combination products is expanding due to the increased prevalence of chronic diseases such as diabetes, cancer, chronic respiratory diseases, and cardiovascular diseases. For instance, Valencell, a top innovator in wearable biometric sensor technology, will be available in January 2023. Valencell specializes in accurate and dependable physiological monitoring for a variety of applications. In order to concentrate its efforts on bringing solutions to market to manage chronic conditions, Valencell has announced plans to develop its own branded product line in the digital health industry.

Restraint

Manufacturing challenges

Drug device combination products might have complicated manufacturing procedures that require specific equipment and expertise. Complex assembly, quality control, and sterile packaging requirements are frequently required for the integration of pharmaceuticals and devices. However, it can be challenging to adhere to good manufacturing practices (GMP) and quality requirements, which can raise production costs and cause supply chain issues.

Opportunity

Governmental initiatives

Various programs are being implemented by governments all over the world to address the growing burden of chronic diseases and advance patient safety. The global market for drug device combination products is expanding as a result of these activities, which are extremely important. For instance, the US FDA acknowledged the important influence of AI and ML in medicine development in September 2021. This year, there were over 100 medication and biologic submissions with AI/ML components. Various stages of drug development, such as drug discovery, clinical research, safety surveillance, and manufacturing, all make use of AI and ML.

Threat

Regulatory obstacles

Drug device combination products must adhere to complicated regulatory standards. It can take a lot of time and money to obtain regulatory licenses and ensure compliance with different regulatory organizations, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). However, manufacturers may have difficulties when it comes to product development, clinical studies, and market access due to strict restrictions and changing standards.

Covid-19 Impact

The disease has expanded to over 100 nations since the COVID-19 viral epidemic in December 2019, and on January 30, 2020, the World Health Organization proclaimed it a public health emergency. However, the global market for medicine-device combination products has been significantly impacted by the COVID-19 epidemic. The market is shaped by rising demand for respiratory devices and innovations in drug-device combinations. However, issues with resource prioritization, manufacturing, and supply chain interruptions have emerged. The pandemic has stimulated industry innovation and cooperation, but the long-term effects are still being witnessed.

The transdermal patches segment is expected to be the largest during the forecast period

The segment for transdermal patches is anticipated to be the largest over the course of the projection period due to the rising demand for drug self-administration in conditions where diseases demand long-term therapy. For instance, a patient with diabetes requires frequent intravenous administration of insulin. Additionally, the need for alternative drug delivery methods is growing due to the pain and increased risk of infection associated with the frequent use of needles to deliver insulin.

The cancer treatment segment is expected to have the highest CAGR during the forecast period

Cancer Treatment segment is expected to have the highest CAGR during the forecast period. By integrating pharmacological substances and medical devices to enhance treatment outcomes, these products offer a distinctive method of cancer therapy. They make it possible to use implantable medication delivery devices, localized radiation therapy, and targeted drug delivery. Additionally, these medications offer synergistic effects and individualized treatment options by combining various therapeutic methods, including chemotherapy, immunotherapy, and targeted therapy.

Region with largest share

Due to the region's vast population, rising frequency of chronic diseases like cancer, and rising healthcare costs, the Asia-Pacific region is anticipated to hold the largest share of the market during the projected period. Moreover, the regional market is growing as a result of increasing physician awareness of the benefits of these products, which include low dosage requirements, timed medication release, direct device-centered infection mitigation using anti-infective medication in combination, and reduced systemic exposure.

Region with highest CAGR

Owing to the adoption of drug-device combination products along with the region's well-established healthcare infrastructure, North America is predicted to have profitable growth over the course of the projection period. Additionally, since many vaccines and other treatments are generated by these industries, there is likely to be a growth in demand for drug-device combination products as corporations invest additional funds in product research and development.

Key players in the market

Some of the key players in Drug Device Combination Products Market include Abbott Laboratories, Allergan plc, Boston Scientific Corporation, C.R. Bard, Medtronic Plc, Mylan N.V., Novartis AG, Stryker Corporation, Teleflex Incorporated, Terumo Corporation and W. L. Gore & Associates, Inc.

Key Developments

In August 2022, Terumo Corporation launched G-Lasta Subcutaneous Injection 3.6 mg BodyPod”, a drug-device combination product co-developed with Kyowa Kirin Co., Ltd. The product received approval from Japan’s Ministry of Health, Labour, and Welfare (MHLW).

In June 2022, Novartis acquired Kedalion Therapeutics and its AcuStream technology that facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. The acquisition enhances the Novartis ophthalmics portfolio, advancing efforts to investigate transformative ophthalmic methods to address unmet patient needs in front-of-eye conditions.

Products Covered
• Infusion Pumps
• Orthopedic Combination Products
• Transdermal Patches
• Photodynamic Therapy Devices
• Drug Eluting Stents
• Wound Care Products
• Antimicrobial Catheters
• Other Products

Applications Covered
• Diabetes
• Cancer Treatment
• Respiratory Problems
• Other Applications

End Users Covered
• Home Care Settings
• Ambulatory Surgery Centers
• Hospitals & Clinics
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Drug Device Combination Products Market, By Product
5.1 Introduction
5.2 Infusion Pumps
5.2.1 Insulin
5.2.2 Implantable
5.2.3 Syringe
5.2.4 Ambulatory
5.3 Orthopedic Combination Products
5.3.1 Antibiotic Bone Cement
5.3.2 Bone Graft Implants
5.4 Transdermal Patches
5.5 Photodynamic Therapy Devices
5.6 Drug Eluting Stents
5.7 Wound Care Products
5.8 Antimicrobial Catheters
5.8.1 Cardiovascular
5.8.2 Urological
5.9 Other Products
6 Global Drug Device Combination Products Market, By Application
6.1 Introduction
6.2 Diabetes
6.3 Cancer Treatment
6.4 Respiratory Problems
6.5 Other Applications
7 Global Drug Device Combination Products Market, By End User
7.1 Introduction
7.2 Home Care Settings
7.3 Ambulatory Surgery Centers
7.4 Hospitals & Clinics
7.5 Other End Users
8 Global Drug Device Combination Products Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Abbott Laboratories
10.2 Allergan plc
10.3 Boston Scientific Corporation
10.4 C.R. Bard
10.5 Medtronic Plc
10.6 Mylan N.V.
10.7 Novartis AG
10.8 Stryker Corporation
10.9 Teleflex Incorporated
10.10 Terumo Corporation
10.11 W. L. Gore & Associates, Inc.
List of Tables
Table 1 Global Drug Device Combination Products Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Drug Device Combination Products Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Drug Device Combination Products Market Outlook, By Infusion Pumps (2021-2030) ($MN)
Table 4 Global Drug Device Combination Products Market Outlook, By Insulin (2021-2030) ($MN)
Table 5 Global Drug Device Combination Products Market Outlook, By Implantable (2021-2030) ($MN)
Table 6 Global Drug Device Combination Products Market Outlook, By Syringe (2021-2030) ($MN)
Table 7 Global Drug Device Combination Products Market Outlook, By Ambulatory (2021-2030) ($MN)
Table 8 Global Drug Device Combination Products Market Outlook, By Orthopedic Combination Products (2021-2030) ($MN)
Table 9 Global Drug Device Combination Products Market Outlook, By Antibiotic Bone Cement (2021-2030) ($MN)
Table 10 Global Drug Device Combination Products Market Outlook, By Bone Graft Implants (2021-2030) ($MN)
Table 11 Global Drug Device Combination Products Market Outlook, By Transdermal Patches (2021-2030) ($MN)
Table 12 Global Drug Device Combination Products Market Outlook, By Photodynamic Therapy Devices (2021-2030) ($MN)
Table 13 Global Drug Device Combination Products Market Outlook, By Drug Eluting Stents (2021-2030) ($MN)
Table 14 Global Drug Device Combination Products Market Outlook, By Wound Care Products (2021-2030) ($MN)
Table 15 Global Drug Device Combination Products Market Outlook, By Antimicrobial Catheters (2021-2030) ($MN)
Table 16 Global Drug Device Combination Products Market Outlook, By Cardiovascular (2021-2030) ($MN)
Table 17 Global Drug Device Combination Products Market Outlook, By Urological (2021-2030) ($MN)
Table 18 Global Drug Device Combination Products Market Outlook, By Other Products (2021-2030) ($MN)
Table 19 Global Drug Device Combination Products Market Outlook, By Application (2021-2030) ($MN)
Table 20 Global Drug Device Combination Products Market Outlook, By Diabetes (2021-2030) ($MN)
Table 21 Global Drug Device Combination Products Market Outlook, By Cancer Treatment (2021-2030) ($MN)
Table 22 Global Drug Device Combination Products Market Outlook, By Respiratory Problems (2021-2030) ($MN)
Table 23 Global Drug Device Combination Products Market Outlook, By Other Applications (2021-2030) ($MN)
Table 24 Global Drug Device Combination Products Market Outlook, By End User (2021-2030) ($MN)
Table 25 Global Drug Device Combination Products Market Outlook, By Home Care Settings (2021-2030) ($MN)
Table 26 Global Drug Device Combination Products Market Outlook, By Ambulatory Surgery Centers (2021-2030) ($MN)
Table 27 Global Drug Device Combination Products Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 28 Global Drug Device Combination Products Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings